<DOC>
	<DOCNO>NCT00312650</DOCNO>
	<brief_summary>Standard treatment recurrent ovarian cancer chemotherapy one drug . One drug , Doxil , cause skin toxicity standard dosages . This study investigate use low dose give frequently combination second drug Gemcitabine .</brief_summary>
	<brief_title>Doxil Gemcitabine Recurrent Ovarian Cancer</brief_title>
	<detailed_description>This study evaluate toxicity Doxil Gemcitabine give every two week basis . Our hypothesis toxicity less standard dose without negative effect survival . Patients also evaluate CT scan every 3 month . Toxicity assess every cycle treatment . Treatment continue toxicity sign progression .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>recurrent platinum resistant ovarian cancer measurable disease prior treatment Doxil Gemzar life expectancy &lt; 3months cardiac ejection fraction &lt; 50 %</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>recurrent</keyword>
	<keyword>progressive</keyword>
</DOC>